Biotechnology

Vor Bio (Nasdaq: VOR) announced the pricing of a public offering of 10,000,000 common shares at $10.00 per share, expecting $100 million in gross proceeds. The offering is anticipated to close around November 12, 2025, subject to closing conditions. Underwriters, including J.P. Morgan and Jefferies, have a 30-day option to purchase up to 1,500,000 additional shares. The shares are being sold under an existing shelf registration. A final prospectus supplement will be filed with the SEC and available via the underwriters.

Evommune, Inc. announced the pricing of its IPO of 9,375,000 shares at $16.00 per share, expected to begin trading on the NYSE (EVMN) on November 6, 2025. The offering is anticipated to close on November 7, 2025, and includes an underwriter option for additional shares. Gross proceeds are projected at $150 million. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are joint book-runners. Evommune will use the funds to advance its pipeline of therapies targeting chronic inflammatory diseases.

Pharming Group will report its Q3 2025 financial results and provide a business update on November 6th. Investors will focus on Ruconest® performance amid competitive HAE therapies and Pharming’s ability to maintain market share. The update will detail R&D pipeline progress, strategic initiatives including collaborations/acquisitions, and capital allocation. Analysts anticipate insights into revenue growth, expense management, and pipeline advancement’s impact on investor sentiment and future prospects. Guidance on full-year performance and strategic priorities will also be closely watched.

Spyre Therapeutics (SYRE) announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, projecting $275.0 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 2,229,729 shares. The offering is expected to close around October 15, 2025, pending customary conditions. Funds will support research and development of antibody therapies for IBD and other immune-mediated conditions. Jefferies, TD Securities, Leerink Partners, and Stifel acted as joint book-running managers.

Adicet Bio, Inc. announced an inducement award to a new employee joining in September 2025. The individual received a non-qualified stock option to purchase 9,800 shares at $0.81 per share, the closing price on the grant date. The options vest over four years with a one-year cliff, contingent upon continued employment. The award was granted under the 2022 Inducement Plan and approved by the independent compensation committee, adhering to Nasdaq Listing Rule 5635(c)(4). Adicet Bio focuses on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.

Revive Therapeutics (RVVTF) is extending its private placement to raise up to $650,000 by issuing units at $0.021 each. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. Having already raised $60,900 in the first tranche, the remaining $589,000 will be used for working capital and settling trade payables. The securities are subject to a four-month and one-day hold period. While providing needed capital, the offering involves significant dilution potential for shareholders.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.